Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585774 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
A Phase 3 study of Chronic Graft Versus Host Disease, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06585774 is a Phase 3 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 240 participants, above the 108-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (122% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06585774, a Phase 3 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INCA034176
- DRUG Corticosteroids
Study Locations (20)
Florida
- Miami Cancer Institute - Miami
- Orlando Health Cancer Institute Downtown Orlando - Orlando
- Memorial Cancer Institute - Pembroke Pines
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Hospital - Detroit
- Corewell Health Hematology Oncology - Grand Rapids
California
- University of California San Diego Medical Center, Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New Jersey
- Hackensack University Medical Center - Hackensack
- Rutgers Cancer Institute of Nj - New Brunswick
New York
- University of Rochester Medical Center - Rochester
- Stony Brook University Medical Center - Stony Brook
Alabama
- University of Alabama Birmingham - Birmingham
Colorado
- Colorado Blood Cancer Institute - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585774
The ClinicalTrials.gov registry entry for NCT06585774 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (122% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06585774 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT06585774 about?
NCT06585774 is a clinical study titled "A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease". This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
What is the current status of trial NCT06585774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2025-01-21. Estimated completion is 2030-03-31.
What conditions does trial NCT06585774 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT06585774?
The interventions under investigation include: Placebo (DRUG), INCA034176 (DRUG), Corticosteroids (DRUG).
Who is sponsoring clinical trial NCT06585774?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585774 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
COMPLETED · Phase 3
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
RECRUITING
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.